Multi-level Molecular Profiling of High Acute Stress: a Clinical Study

Sponsor
University Hospital, Bonn (Other)
Overall Status
Recruiting
CT.gov ID
NCT05144022
Collaborator
(none)
50
1
2
4
12.5

Study Details

Study Description

Brief Summary

Although it is well known that stress plays an important role in the development of neuropsychiatric diseases, the precise role and molecular effects of stress have only been poorly understood. For example, autophagy is essential for energy and cellular homeostasis through protein catabolism, and dysregulation results in compromised proteostasis, stress-coping behavior, and excessive secretion of signaling molecules and inflammatory factors. Therefore, the aim of the project is to analyze the clinical effects of a bungee jump resembling an acute stress event in correlation to autophagy and other underlying, multi-level molecular profiling. Specifically, it is planned to perform multi-level molecular profiling and sleep analysis in a cohort of healthy male individuals before, during, and after a bungee jump compared to a control cohort of healthy males not undergoing a stress event. The resulting findings will advance the role of autophagy during the stress response and hence in the development of psychiatric disorders, and possibly investigate alternative treatment venues on a molecular level, and finally contribute to a better clinical outcome.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Bungee jump
N/A

Detailed Description

Although it is well known that stress plays an important role in the development of neuropsychiatric diseases, the molecular effects of stress have only been poorly understood. So far it is known that stress leads to an activation of the stress hormone axis followed by an increased release of the stress hormone and glucocorticoid cortisol. Glucocorticoids bind to glucocorticoid receptors that initiate a cellular signal cascade. However, it can be assumed that other factors are involved but a profound understanding of the stress response at the molecular level has not yet been performed yet.

Using a so-called "multi-omics approach" it is possible to determine changes in a large number of molecular groups, such as proteins or lipids to research the underlying mechanisms of diseases. While multi-omics analyzes have already helped gain elementary knowledge in a large number of somatic diseases, the molecular effects of acute stress have not been addressed yet. This will be the primary focus of this study. To achieve this an acute, concise stress reaction closely resembling a genuine stress response is desired. In previous studies, it was shown that bungee jumping triggers such a short, intense stress reaction and the corresponding activation of the stress hormone axis.

To achieve this a cohort of 25-30 healthy male individuals who undergo a bungee jump resembling an acute stress event will be compared to a cohort of 10-20 healthy males who undergo the same experimental design without undertaking a bungee jump or other stress intervention. At different time points (baseline, shortly before and after the intervention, at multiple time points during the intervention as well as around one week follow up after the intervention) serval psychometrical questionnaires will be gathered and blood will be collected. A dexamethasone inhibition test will be performed before the stress intervention. Sleep quality will be additionally assessed during the entire course of the study by actigraphy. On selected days blood will be collected. Following, autophagy activity will be assessed by Western Blot analysis, and mass spectrometry-based proteomics, phosphoproteomics, metabolomics, and lipidomics will be performed. Bioinformatic analysis, statistical evaluation, quality control, and in silico pathway analyses will then specifically identify factors and cascades of relevance.

The aim of the project is to analyze the clinical effects of an acute stress event in correlation to the underlying, multi-level molecular profiling. Longitudinal multi-omic profiling including proteome, metabolome, lipidome, and epigenetic changes will reveal time-series analysis of thousands of molecular changes and an orchestrated composition of autophagy depended signaling. The resulting findings will advance the role of autophagy in the development of psychiatric disorders, and possibly investigate alternative treatment venues on a molecular level, and finally contribute to a better clinical outcome.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
2 groups each undergoing one out of two conditions ("high stress" (bungee jump) or "no stress" (control))2 groups each undergoing one out of two conditions ("high stress" (bungee jump) or "no stress" (control))
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Multi-level Molecular Profiling of High Acute Stress
Actual Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Jan 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Interventions group: High stress condition (bungee jump)

25-30 healthy male volunteers participating in a bungee jump

Behavioral: Bungee jump
Bungee jump from a cran

Placebo Comparator: Control group: No stress condition

10-15 healthy males serving as a control group without undergoing a stress event/intervention

Behavioral: Bungee jump
Bungee jump from a cran

Outcome Measures

Primary Outcome Measures

  1. Proteomics and autophagy processes [change from baseline to the stress intervention and a 5- 7 day follow up]

    Change in protein levels of autophagy biomarkers (LC3II & p62) of isolated PBMCs (peripheral blood mononuclear cells) by Western Blotting.

Secondary Outcome Measures

  1. Proteome patterns [change from baseline to the stress intervention and a 5- 7 day follow up]

    Change in protein levels and protein phosphorylation by untargeted mass spectrometry-based proteomics and phosphoproteomics of isolated PBMCs (peripheral blood mononuclear cells).

  2. Metabolic processes [change from baseline to the stress intervention and a 5- 7 day follow up]

    Metabolic measurements by mass spectrometry, in order to determine variations in plasma metabolites, including targeted analysis of steroid hormones

  3. Lipid profiling [change from baseline to the stress intervention and a 5- 7 day follow up]

    Targeted and quantitative analysis by mass spectrometry of change in plasma Lipids.

  4. Saliva Cortisol Levels [comparison between groups]

    Saliva Cortisol Levels in nmol per Liter (nmol/L) after dexamethasone intake will be evaluated and compared ton the control group

  5. Sleep Efficiency [change from baseline to the stress intervention and a 5- 7 day follow up]

    Assessment of Sleep Efficiency (total time in bed/time asleep during night) by GenActive Actigraphs

  6. Overall sleep Quality [change from baseline to the stress intervention and a 5- 7 day follow up]

    Sleep diary to assess overall sleep quality assessed as ratio of the total time spent asleep (in hours) to the total amount of time spent in bed (in hours) per night

  7. Sleep Quality (PSQI) [change from baseline to the stress intervention and a 5- 7 day follow up]

    Pittsburgh Sleep Quality Index (PSQI): self-report questionnaire to assess sleep quality over a 1-month time interval consisting of 19 individual items.

  8. Mental well-being (WEMWBS) [change from baseline to the stress intervention and a5- 7 day follow up]

    Warwick-Edinburgh Mental Well-being Scale (WEMWBS): self-reported 14-item scale to assess Overall mental wellbeing, minimum value 14, maximum value 70, high score indicating high well-being

  9. Resilience behavior (Wagnild &Young) [change from baseline to the stress intervention and a 5- 7 day follow up]

    Resilience scale (Wagnild &Young): self-reported 25-item scale to assess overall resilience, minimum value 25, maximum value 175, high score indicating higher resilience

  10. Phosphoproteome patterns [change from baseline to the stress intervention and a 5- 7 day follow up]

    Change in protein phosphorylation by untargeted mass spectrometry-based phosphoproteomics of isolated PBMCs (peripheral blood mononuclear cells).

  11. Ubiquitinome patterns [change from baseline to the stress intervention and a 5- 7 day follow up]

    Change in protein ubiquitination levels by untargeted mass spectrometry-based proteomics of isolated PBMCs (peripheral blood mononuclear cells).

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 40 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Present written declaration of consent

  • Healthy

  • Male

  • BMI between 18,5 and 24,9 and body weight between 50kg and 120kg

Exclusion Criteria:
  • Insufficient linguistic communication

  • Drug abuse or alcohol dependency

  • regular medication except for L-thyroxine or antihistamines

  • known severe eye disease or severely impaired eyesight or hearing

  • a known disease of the cardiovascular system, hypertension higher than 160/90mmHg

  • known pulmonary disease, e.g. bronchial asthma

  • known fractures of the spine or skeletal system of the lower extremity

  • surgery within the last 4 to six months

  • intervention group: fear of heights

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Bonn, Clinic for psychiatry and psychotherapy Bonn Germany 53111

Sponsors and Collaborators

  • University Hospital, Bonn

Investigators

  • Principal Investigator: Nils Gassen, Dr. rer. nat., University Hospital, Bonn

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dr. Nils Gassen, Principal Investigator, University Hospital, Bonn
ClinicalTrials.gov Identifier:
NCT05144022
Other Study ID Numbers:
  • HighStress
First Posted:
Dec 3, 2021
Last Update Posted:
Dec 3, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Nils Gassen, Principal Investigator, University Hospital, Bonn

Study Results

No Results Posted as of Dec 3, 2021